Search hospitals > Illinois > Chicago
Advocate Illinois Masonic Medical Center
Claim this profileChicago, Illinois 60657
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
106 reported clinical trials
19 medical researchers
Summary
Advocate Illinois Masonic Medical Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Advocate Illinois Masonic Medical Center is involved with conducting 106 clinical trials across 249 conditions. There are 19 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Adam P. Siegel.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Rubina QamarAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Breast Cancer
Expert in Cancer
26 reported clinical trials
72 drugs studied
Thomas J. SaphnerAurora Saint Luke's Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
21 reported clinical trials
46 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West3 years of reported clinical research
Studies Cancer
Studies Solid Tumors
14 reported clinical trials
57 drugs studied
Adam P. SiegelAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
10 reported clinical trials
30 drugs studied
Clinical Trials running at Advocate Illinois Masonic Medical Center
Breast Cancer
Lung Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Cancer
Rectal Cancer
Ovarian Cancer
Recurrence
Fallopian Tube Cancer
Bile Duct Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Omitting Radiation Therapy
for Breast Cancer
This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Advocate Illinois Masonic Medical Center?
Advocate Illinois Masonic Medical Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Advocate Illinois Masonic Medical Center is involved with conducting 106 clinical trials across 249 conditions. There are 19 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Adam P. Siegel.